Breaking News

Financial Report: Teva 2Q11

Azilect and Copaxone achieve record sales, fueling growth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Teva 2Q11 2Q Revenues: $4.2 billion (+11%) 2Q Earnings: $576.0 million (-28%) YTD Revenues: $8.3 billion (+11%) YTD Earnings: $1.3 billion (-11%) Comments: Global respiratory product sales totaled $240 million in the quarter, up 9%. Women’s health product sales were $119 million, up 45% driven by Theramex product sales. In-market sales of Azilect reached a record $97 million in the quarter, up 38%, and in-market sales of Copaxone were a record $957 million, up 24%. API sales were $183...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters